Streamex Corp. — fact timeline

Donald E. Foley resigned as director at Streamex Corp..

“On February 19, 2024, David Weild IV, Donald E. Foley, Patrick J. Gallagher and James J. Barry, resigned from their positions as directors of the Company, effective as of the same date.”

David Weild IV resigned as director at Streamex Corp..

“On February 19, 2024, David Weild IV, Donald E. Foley, Patrick J. Gallagher and James J. Barry, resigned from their positions as directors of the Company, effective as of the same date.”

Steve Buhaly resigned as Chief Financial Officer at Streamex Corp..

“On February 15, 2024, Steve Buhaly resigned from his position as the Chief Financial Officer of BioSig Technologies, Inc. (the “ Company ”), effective as of the same date.”

Streamex Corp. announced a restructuring with charges of approximately $713,924 (sixteen employees).

“On January 28, 2024, management of the Company commenced a workforce reduction intended to reduce annual cash burn by approximately 50%, which was completed as of January 31, 2024. The workforce reduction consisted of the departure of sixteen employees, effective as of January 31, 2024 (the “Effective Date”) and included the departure of John Sieckhaus, the Company’s Chief Operating Officer, and Gray Fleming, the Company’s Chief Commercial Officer. In connection with the reduction in force, the Company estimates it will incur total aggregate costs of approximately $713,924, which consists of one-time departure fees and severance packages for employees in equity, based on factors including years of employment, in the estimated amount of $135,288 and retention bonuses paid in equity in the estimated amount of $578,636.”

Streamex Corp. announced a restructuring with charges of approximately $919,249 (sixteen employees).

“the Company estimates it will incur total aggregate costs of approximately $919,249, which consists of: payments for consulting services paid in equity in the estimated amount of $205,325; one-time departure fees and severance packages for employees in equity, based on factors including years of employment, in the estimated amount of $135,288; and retention bonuses paid in equity in the estimated amount of $578,636.”

Gray Fleming departed as other_named_officer at Streamex Corp..

“Mr. Sieckhaus and Mr. Fleming, effective as of the Effective Date, are departing from the Company.”

John Sieckhaus departed as other_named_officer at Streamex Corp..

“Mr. Sieckhaus and Mr. Fleming, effective as of the Effective Date, are departing from the Company.”

Streamex Corp.: Reverse stock split amendment to the Certificate of Incorporation at a ratio of 1-for-10 (effective 2024-02-01).

“On January 31, 2024, the Company filed the Reverse Stock Split Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, effective as of 4:05 p.m. (New York time) on February 1, 2024.”

Streamex Corp. entered into Securities Purchase Agreement with certain accredited and institutional investors valued at gross proceeds from this offering were $1,040,000.11 (effective 2024-01-12).

“On January 12, 2024, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited and institutional investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 2,607,170 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and warrants (the “Warrants”) to purchase up to 1,303,585 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Warrants, the “Securities”), at a purchase price of $0.3989 per Share and a Warrant to purchase one-half of a Share.”

Streamex Corp. shareholders approved Approve issuance of shares underlying warrants in excess of 20% of outstanding common stock for purposes of complying with Nasdaq Listing Rule 5635(d). at the 2023-12-27 meeting.

“(1) A proposal to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) underlying certain warrants issued by the Company pursuant to the terms of (i) that certain Securities Purchase Agreement, dated November 8, 2023, by and between the Company and an institutional investor and (ii) that certain Engagement Agreement, dated October 31, 2023, by and between the Company and H.C. Wainwright & Co., LLC, in an amount equal to or in excess of 20% of the Common Stock outstanding immediately prior to the issuance of such warrants (the “Issuance Proposal”).”

Streamex Corp. received a nasdaq deficiency notice notice regarding market value (rules 5810(c)(3)(C), 5550(b)(3)).

“n which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(C). In order to regain compliance with Nasdaq’s minimum MVLS requirement, the Company’s MVLS must close at $35,000,000 or more for”

Streamex Corp. shareholders approved Ratification of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-18 meeting.

“Approval of the Auditor Ratification Proposal: For Against Abstain Broker Non-Votes 53,861,582 589,954 288,977 -”

Streamex Corp. shareholders approved Approval of amendment to 2023 Long-Term Incentive Plan to increase authorized shares by 3,500,000 at the 2023-12-18 meeting.

“Approval of the Plan Amendment Proposal: For Against Abstain Broker Non-Votes 36,154,958 2,363,847 693,288 15,528,420”

Streamex Corp. shareholders approved Approval of reverse stock split at a ratio between 1-for-2 and 1-for-10 at the 2023-12-18 meeting.

“Approval of the Reverse Stock Split Proposal: For Against Abstain Broker Non-Votes 47,899,780 6,606,612 234,121 -”

Streamex Corp. shareholders approved Election of seven directors to serve until 2024 annual meeting at the 2023-12-18 meeting.

“Each of the following nominees for director received the number of votes set forth opposite his name, constituting in each case a plurality of the votes cast at the Annual Meeting for the election of such director to serve as a director on the Board until the 2024 Annual Meeting or until his successor has duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Kenneth L. Londoner 37,869,038 1,343,055 15,528,420 David Weild IV 38,069,486 1,142,607 15,528,420 Patrick J. Gallagher 37,801,725 1,410,368 15,528,420 Donald E. Foley 37,930,829 1,281,264 15,528,420 James J. Barry 38,074,136 1,137,957 15,528,420 Frederick D. Hrkac 38,189,433 1,022,660 15,528,420 James L. Klein 36,452,950 2,759,143 15,528,420”

Streamex Corp. entered into Securities Purchase Agreement with institutional investor valued at 6,996,922 shares of common stock at $0.3573 per share, Series A and Series B warrants, aggregate gro (effective 2023-11-08).

“On November 8, 2023, BioSig Technologies, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Offering”), (i) 6,996,922 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), (ii) Series A warrants (the “Series A Warrants”) to purchase up to 6,996,922 shares of Common Stock, and (iii) Series B Warrants (the “Series B Warrants”, and together with the Series A Warrants, the “Series Warrants”) to purchase up to 6,996,922 shares of Common Stock, at a purchase price of $0.3573 per Share and associated Series Warrants.”

Streamex Corp.: Adopted Amendment No. 3 to the Amended and Restated Bylaws, changing voting requirements for director elections to a plurality of votes cast and for other matters to a majority of votes cast (excluding abstentions and broker non-votes) (effective 2023-11-02).

“On November 2, 2023, the board of directors of BioSig Technologies, Inc. (the “ Company ”) adopted Amendment No. 3 to the Amended and Restated Bylaws of the Company, as amended (the “ Third Amendment ”), which became effective as of the same date.”

Streamex Corp. terminated Sales Agreement with Ascendiant Capital Markets, LLC (effective 2023-11-06).

“On November 1, 2023, the Company delivered written notice to the Agent to terminate the Sales Agreement, effective November 6, 2023, pursuant to Section 13(b) of the Sales Agreement.”

Streamex Corp. entered into Securities Purchase Agreement with certain accredited investors valued at $597,496.72 (effective 2023-10-12).

“On October 12, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,129,996 shares (the “Shares”) of the Company’s common stock”

Streamex Corp. entered into Securities Purchase Agreement with certain accredited and institutional investors valued at $810,200.84 (effective 2023-09-21).

“On September 21, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited and institutional investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,458,770 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $0.5554 per share, and warrants (the “Warrants”) to purchase up to 729,385 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Warrants, the “Securities”), at an exercise price of $0.4929 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $810,200.84 (the “September PIPE”).”

Streamex Corp. terminated Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. (effective 2023-09-15).

“On September 15, 2023, the Company delivered written notice to Cantor to terminate the Cantor Agreement, effective September 15, 2023, pursuant to Section 12(b) of the Cantor Agreement.”

Streamex Corp. entered into Sales Agreement with Ascendiant Capital Markets, LLC (effective 2023-09-15).

“On September 15, 2023, BioSig Technologies, Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Ascendiant Capital Markets, LLC, to act as the Company’s sales agent or principal (“Agent”), with respect to the issuance and sale of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time in an at the market offering.”

Streamex Corp. entered into Securities Purchase Agreement with certain accredited investors valued at $549,999.29 (effective 2023-09-12).

“On September 12, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 990,954 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $0.55502 per share, and warrants (the “Warrants”) to purchase up to 495,477 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Warrants, the “Securities”), at an exercise price of $0.49252 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $549,999.29”

Streamex Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 6, 2023, BioSig Technologies, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between July 25, 2023, to September 5, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, o”

Streamex Corp. entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. (effective 2023-08-18).

“On August 18, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., to act as the Company’s sales agent or principal (“Agent”), with respect to the issuance and sale of the Company’s shares of common stock”

Streamex Corp. entered into Securities Purchase Agreement with a certain accredited investor valued at $1,499,999.79 (effective 2023-07-31).

“On July 31, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain accredited investor (the “Investor”), pursuant to which the Company sold to the Investor an aggregate of 1,467,624 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $1.02206 per share, and a warrant (the “Warrant”) to purchase up to 733,812 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Warrant, the “Securities”), at an exercise price of $0.95956 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $1,499,999.79 (the “July PIPE”).”

Streamex Corp. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at $495,000 (effective 2023-07-19).

“On July 19, 2023, BioSig AI Sciences, Inc., f/k/a NeuroClear Technologies Inc. (“BioSig AI”), a subsidiary of BioSig Technologies, Inc. (“BioSig”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which BioSig AI agreed to sell an aggregate of 495,000 shares (the “Shares”) of BioSig AI’s common stock, par value $0.001 per share (the “Common Stock”) for an aggregate purchase price of $495,000”

Streamex Corp. entered into Securities Purchase Agreement with certain accredited investors valued at $1,710,000 (effective 2023-06-30).

“On June 30, 2023, BioSig AI Sciences, Inc., f/k/a NeuroClear Technologies Inc. (“BioSig AI”), a subsidiary of BioSig Technologies, Inc. (“BioSig”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which BioSig AI agreed to sell an aggregate of 1,710,000 shares (the “Shares”) of BioSig AI’s common stock, par value $0.001 per share (the “Common Stock”) for an aggregate purchase price of $1,710,000 (the “BioSig AI Private Placement”).”

Streamex Corp. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at $2,500,747.51 (effective 2023-05-16).

“On May 16, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,798,452 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $1.3905 per share, and warrants (the “Warrants”) to purchase up to 899,226 shares of Common Stock (the “Warrant Shares” and together with the Shares and Warrants, the “Securities”), at an exercise price of $1.328 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $2,500,747.51 (the “May PIPE”).”

Streamex Corp. entered into Securities Purchase Agreement with certain accredited and institutional investors valued at $945,001.40 (effective 2023-04-18).

“On April 18, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited and institutional investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 792,454 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $1.1925 per share, and warrants (the “Warrants”) to purchase up to 396,227 shares of Common Stock (the “Warrant Shares” and together with the Shares and Warrants, the “Securities”), at an exercise price of $1.13 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $945,001.40 (the “April PIPE”).”

Streamex Corp. entered into Securities Purchase Agreement with certain accredited investors valued at $1,017,889.00 (effective 2023-03-24).

“On March 24, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 935,130 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $1.0885 per share, and warrants (the “Warrants”) to purchase up to 467,565 shares of Common Stock (the “Warrant Shares” and together with the Shares and Warrants, the “Securities”), at an exercise price of $1.026 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $1,017,889.00 (the “March PIPE”).”

Streamex Corp. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at aggregate consideration of $1,719,983.01 (effective 2023-03-14).

“On March 14, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,550,540 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $1.10928 per share, and warrants (the “Warrants”) to purchase up to 775,270 shares of Common Stock (the “Warrant Shares” and together with the Shares and Warrants, the “Securities”), at an exercise price of $1.04678 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $1,719,983.01 (the “March PIPE”).”

Streamex Corp. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate consideration of $409,994.75 (effective 2023-02-08).

“On February 8, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 382,308 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $1.07242 per share, and warrants (the “Warrants”) to purchase up to 191,154 shares of Common Stock (the “Warrant Shares” and together with the Shares and Warrants, the “Securities”), at an exercise price of $1.00992 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $409,994.75.”

Streamex Corp. shareholders approved A proposal to approve the BioSig Technologies, Inc. 2023 Long-Term Incentive Plan at the 2023-02-07 meeting.

“The number of votes cast for and against and the number of abstentions and broker non-votes with respect to the matter voted upon are set forth below: (1) A proposal to approve the BioSig Technologies, Inc. 2023 Long-Term Incentive Plan: For Against Abstain Broker Non-Votes 24,741,946 1,615,076 421,207 -”

Streamex Corp. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at $1,366,994.90 (effective 2023-02-03).

“On February 3, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 1,591,750 shares (the “Shares”) of the Company’s common stock”

Steve Buhaly was appointed as Chief Financial Officer at Streamex Corp..

“On February 2, 2023, the Board appointed Mr. Steve Buhaly as the Chief Financial Officer of the Company, whose employment will commence on February 6, 2023.”

Steve Chaussy was terminated as Chief Financial Officer at Streamex Corp..

“On February 2, 2023, the BioSig Technologies, Inc. (the “ Company ”) entered into a General Release and Severance Agreement (the “ Release Agreement ”) with Steve Chaussy, Chief Financial Officer of the Company, pursuant to which Mr. Chaussy’s employment with the Company will terminate upon the earlier of April 28, 2023, or the date of an earlier termination”

Steve Buhaly was appointed as Chief Financial Officer at Streamex Corp..

“On February 2, 2023, the Board appointed Mr. Steve Buhaly as the Chief Financial Officer of the Company, whose employment will commence on February 6, 2023.”

Steve Chaussy was terminated as Chief Financial Officer at Streamex Corp..

“On February 2, 2023, the BioSig Technologies, Inc. (the “ Company ”) entered into a General Release and Severance Agreement (the “ Release Agreement ”) with Steve Chaussy, Chief Financial Officer of the Company, pursuant to which Mr. Chaussy’s employment with the Company will terminate at such point when his services are no longer required”

Streamex Corp. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at aggregate consideration of $159,997.87 (effective 2023-01-25).

“On January 25, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 196,872 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $0.8127 per share, and warrants (the “Warrants”) to purchase up to 98,436 shares of Common Stock (the “Warrant Shares” and together with the Shares and Warrants, the “Securities”), at an exercise price of $0.7502 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $159,997.87.”

Streamex Corp. entered into Purchase Agreement with an accredited investor (the "Investor") valued at $1,299,998.75 (effective 2023-01-23).

“On January 23, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which the Company sold to the Investor 1,665,384 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $0.7806 per share, and a warrant (the “Warrant”) to purchase up to 832,692 shares of Common Stock (the “Warrant Shares” and together with the Shares and Warrant, the “Securities”), at an exercise price of $0.7181 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for consideration of $1,299,998.75.”

Streamex Corp. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at $1,254,884.28 (effective 2023-01-10).

“On January 10, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 2,178,316 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $0.57608 per share, and warrants (the “Warrants”) to purchase up to 1,089,158 shares of Common Stock (the “Warrant Shares” and together with the Shares and Warrants, the “Securities”), at an exercise price of $0.51358 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $1,254,884.28.”

Streamex Corp. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at $1,098,091.79 (effective 2022-12-21).

“On December 21, 2022, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 2,161,598 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $0.508 per share, and warrants (the “Warrants”) to purchase up to 1,080,799 shares of Common Stock (the “Warrant Shares” and together with the Shares and Warrants, the “Securities”), at an exercise price of $0.4455 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $1,098,091.79 (the “December PIPE”).”

Streamex Corp.: Lowered the quorum threshold at stockholder meetings to one-third of voting power (effective 2022-12-27).

“The Second Amendment amends and restates Article II, Section 2.6 of the Company’s Amended and Restated Bylaws in its entirety to lower the threshold required to achieve a quorum at all meetings of the Company’s stockholders to one-third of the voting power of the stock issued, outstanding and entitled to vote, present in person or represented by proxy.”

Streamex Corp. shareholders approved Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the 2022 fiscal year at the 2022-12-20 meeting.

“(4) Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the 2022 fiscal year: For Against Abstain Broker Non-Votes 31,860,583 279,296 67,772 -”

Streamex Corp. shareholders approved Advisory vote on the compensation of the Company's named executive officers as described in the 2022 Proxy Statement at the 2022-12-20 meeting.

“(3) Approval of an advisory vote on the compensation of the Company's named executive officers as described in the 2022 Proxy Statement: For Against Abstain Broker Non-Votes 18,486,832 2,925,924 171,937 10,622,958”

Streamex Corp. shareholders approved Approval of an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split of all outstanding shares of common stock at a ratio in the range of 1-for-2 to 1-for-10 at the 2022-12-20 meeting.

“(2) Approval of the Reverse Stock Split Proposal: For Against Abstain Broker Non-Votes 28,361,739 3,721,643 124,269 -”

Streamex Corp. shareholders approved Election of seven directors to serve until the Company's 2023 annual meeting of stockholders or until their successors have been duly elected and qualified at the 2022-12-20 meeting.

“Each of the following nominees for director received the number of votes set forth opposite his name, constituting in each case a plurality of the votes cast at the Annual Meeting for the election of such director to serve for a term of one year or until his successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Kenneth L. Londoner 19,582,352 2,002,341 10,622,958 James J. Barry 19,294,323 2,290,370 10,622,958 David Weild IV 19,691,976 1,892,717 10,622,958 Patrick J. Gallagher 18,798,724 2,785,969 10,622,958 Donald E. Foley 18,956,636 2,628,057 10,622,958 Frederick D. Hrkac 19,274,781 2,309,912 10,622,958 James L. Klein 19,903,747 1,680,946 10,622,958”

Streamex Corp. terminated ATM Sales Agreement with Virtu Americas LLC valued at up to $10,000,000 (effective 2022-12-01).

“On November 30, 2022, the Company delivered written notice to the Agent to terminate the Sales Agreement, effective December 1, 2022 pursuant to Section 13(b) of the Sales Agreement.”

Streamex Corp. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 22, 2022, BioSig Technologies, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market (“Nasdaq”) informing the Company that the Company failed to maintain a minimum of $2,500,000 in stockholders’ equity required for continued listing (the “Stockholders’ Equity Requirement”) on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) based upon the reported stockholders’ equity of $1,834,000 in the Company’s quarterly report on Form 10-Q for the period ended September 30, 2022 and that as of November 22, 2022, the Company did not meet the alternative c”